Oxycodone
- Generic Name
- Oxycodone
- Brand Names
- Endocet, Endodan Reformulated May 2009, Nalocet, Oxaydo, Oxy.IR, Oxycontin, Oxyneo, Percocet, Prolate, Rivacocet, Roxicet, Roxicodone, Roxybond, Targin, Targiniq, Xolox, Xtampza
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21NO4
- CAS Number
- 76-42-6
- Unique Ingredient Identifier
- CD35PMG570
- Background
Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period. The first oxycodone containing product, Percodan, wa...
- Indication
Oxycodone is indicated for the treatment of moderate to severe pain. There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.
- Associated Conditions
- Severe Acute Pain, Severe Pain, Severe, Chronic Pain, Acute, moderate Pain, Chronic, moderate Pain
- Associated Therapies
- -
Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms
- Conditions
- Interventions
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT05142267
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures
- Conditions
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 188
- Registration Number
- NCT05076110
- Locations
- 🇺🇸
Mayo clinic, Rochester, Minnesota, United States
Ketorolac vs Oxycodone for Great Toe Arthrodesis
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT05054868
- Locations
- 🇺🇸
Amy Loveland, Baltimore, Maryland, United States
Evaluation of Oral PF614 Relative to OxyContin
- Conditions
- Interventions
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Ensysce Biosciences
- Target Recruit Count
- 84
- Registration Number
- NCT05043766
- Locations
- 🇺🇸
PRA Health Sciences-Early Development Services, Salt Lake City, Utah, United States
Non-Opioid Pain Medications After Intracapsular Adenotonsillectomy
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- David Chi, MD
- Target Recruit Count
- 73
- Registration Number
- NCT04791761
- Locations
- 🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
ESP in Breast Surgery Due to Cancer
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Medical University of Lublin
- Target Recruit Count
- 75
- Registration Number
- NCT04726878
- Locations
- 🇵🇱
II Department of Anesthesia and Intensive Care, Medical University of Lublin, Lublin, Poland
Reducing the Abuse Liability of Prescription Opioids
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2020-10-14
- Target Recruit Count
- 15
- Registration Number
- NCT04587115
- Locations
- 🇺🇸
Westgate Pain Clinic, San Antonio, Texas, United States
Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated Forearm Injuries
- Conditions
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 200
- Registration Number
- NCT04523623
Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 68
- Registration Number
- NCT04429022
- Locations
- 🇺🇸
Millard Fillmore Suburban Hospital, Williamsville, New York, United States
Non-analgesic Effects Produced by Equipotent Analgesic Doses of Sufentanil, Hydromorphone, and Oxycodone
- Conditions
- Interventions
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04396587
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.